GT Biopharma Company Insiders
| GTBP Stock | USD 3.65 0.13 3.44% |
GT Biopharma's insiders are aggressively buying. The analysis of the overall insider sentiment regarding GT Biopharma suggests that virtually all insiders are extremely bullish. GT Biopharma employs about 2 people. The company is managed by 13 executives with a total tenure of roughly 40 years, averaging almost 3.0 years of service per executive, having 0.15 employees per reported executive.
| Anthony Cataldo Chairman Chairman of the Board, CEO |
| Steven Weldon President President CFO, Director |
GT Biopharma's Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2023-04-11 | Michael Martin Breen | Acquired 1666 @ 15 | View | ||
| 2023-04-06 | Manu Ohri | Acquired 1666 @ 15 | View |
Monitoring GT Biopharma's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
GTBP |
GT Biopharma's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with GT Biopharma's future performance. Based on our forecasts, it is anticipated that GTBP will maintain a workforce of slightly above 50 employees by May 2024.GT Biopharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.5502) % which means that it has lost $0.5502 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7909) %, meaning that it created substantial loss on money invested by shareholders. GT Biopharma's management efficiency ratios could be used to measure how well GT Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of 04/24/2024, Return On Tangible Assets is likely to drop to -0.57. In addition to that, Return On Capital Employed is likely to drop to -1.91. At this time, GT Biopharma's Total Current Liabilities is relatively stable compared to the past year. As of 04/24/2024, Change To Liabilities is likely to grow to about 8.5 M, while Liabilities And Stockholders Equity is likely to drop slightly above 13.2 M.As of 04/24/2024, Common Stock Shares Outstanding is likely to drop to about 1.3 M. In addition to that, Net Loss is likely to drop to about (54.8 M)
GT Biopharma Workforce Comparison
GT Biopharma is rated below average in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 527. GT Biopharma adds roughly 2.0 in number of employees claiming only tiny portion of equities under Health Care industry.
GT Biopharma Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific GT Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on GT Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, GT Biopharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2022-09-01 | 6.0 | 6 | 1 | 450,000 | 100,000 |
| 2021-03-01 | 9.0 | 9 | 1 | 1,153,790 | 30,000 |
| 2020-12-01 | 0.1875 | 3 | 16 | 5,083 | 780,000 |
| 2017-09-01 | 0.6667 | 2 | 3 | 7,696,495 | 0.00 |
| 2016-06-01 | 1.0 | 1 | 1 | 250,000 | 675,000 |
| 2011-06-01 | 0.5 | 1 | 2 | 0.00 | 1,027,778 |
| 2010-12-01 | 0.2857 | 2 | 7 | 1,400,000 | 3,050,000 |
| 2010-03-01 | 1.0 | 2 | 2 | 2,610,227 | 6,804,081 |
| 2005-12-01 | 6.0 | 6 | 1 | 1,338,000 | 30,000 |
| 2004-12-01 | 6.0 | 6 | 1 | 450,000 | 50,000 |
| 2004-06-01 | 1.75 | 7 | 4 | 155,000 | 100,000 |
| 2003-12-01 | 0.5 | 5 | 10 | 511,561 | 180,127 |
GT Biopharma Notable Stakeholders
A GT Biopharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as GT Biopharma often face trade-offs trying to please all of them. GT Biopharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting GT Biopharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Anthony Cataldo | Chairman of the Board, CEO | Profile | |
| Steven Weldon | President CFO, Director | Profile | |
| Shawn Cross | President COO | Profile | |
| Peter Kiener | Director | Profile | |
| Geoffrey Davis | Director | Profile | |
| John Bonfiglio | Director | Profile | |
| Michael Breen | Interim Chairman | Profile | |
| PharmD MBA | Chief Officer | Profile | |
| Raymond Urbanski | Chief Medical Officer | Profile | |
| Manu Ohri | Chief Officer | Profile | |
| Jeffrey MD | Consulting Advisor | Profile | |
| Gregory MD | Chief RD | Profile | |
| MPH MBA | VP Management | Profile |
About GT Biopharma Management Performance
The success or failure of an entity such as GT Biopharma often depends on how effective the management is. GT Biopharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of GTBP management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the GTBP management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.54) | (0.57) | |
| Return On Capital Employed | (1.82) | (1.91) | |
| Return On Assets | (0.54) | (0.51) | |
| Return On Equity | (1.02) | (1.07) |
The data published in GT Biopharma's official financial statements usually reflect GT Biopharma's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of GT Biopharma. For example, before you start analyzing numbers published by GTBP accountants, it's critical to develop an understanding of what GT Biopharma's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of GT Biopharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, GT Biopharma's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in GT Biopharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of GT Biopharma. Please utilize our Beneish M Score to check the likelihood of GT Biopharma's management manipulating its earnings.
GT Biopharma Workforce Analysis
Traditionally, organizations such as GT Biopharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare GT Biopharma within its industry.GT Biopharma Manpower Efficiency
Return on GT Biopharma Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 3.8M | |
| Net Loss Per Executive | 584.4K | |
| Working Capital Per Employee | 3.7M | |
| Working Capital Per Executive | 571K |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GT Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in GTBP Stock, please use our How to Invest in GT Biopharma guide.Note that the GT Biopharma information on this page should be used as a complementary analysis to other GT Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for GTBP Stock analysis
When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |
Is GT Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GT Biopharma. If investors know GTBP will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GT Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.58) | Return On Assets (0.55) | Return On Equity (0.79) |
The market value of GT Biopharma is measured differently than its book value, which is the value of GTBP that is recorded on the company's balance sheet. Investors also form their own opinion of GT Biopharma's value that differs from its market value or its book value, called intrinsic value, which is GT Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GT Biopharma's market value can be influenced by many factors that don't directly affect GT Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GT Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if GT Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GT Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.